Vestmark Advisory Solutions Inc. Reduces Stake in DexCom, Inc. (NASDAQ:DXCM)

Vestmark Advisory Solutions Inc. reduced its position in DexCom, Inc. (NASDAQ:DXCMGet Rating) by 67.0% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 6,452 shares of the medical device company’s stock after selling 13,110 shares during the period. Vestmark Advisory Solutions Inc.’s holdings in DexCom were worth $520,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors and hedge funds have also recently modified their holdings of the company. Gilbert & Cook Inc. boosted its stake in shares of DexCom by 3.2% in the 3rd quarter. Gilbert & Cook Inc. now owns 5,140 shares of the medical device company’s stock worth $596,000 after buying an additional 160 shares during the last quarter. Global Retirement Partners LLC boosted its stake in shares of DexCom by 27.1% in the 3rd quarter. Global Retirement Partners LLC now owns 806 shares of the medical device company’s stock worth $97,000 after buying an additional 172 shares during the last quarter. The Manufacturers Life Insurance Company boosted its stake in shares of DexCom by 2.3% in the 3rd quarter. The Manufacturers Life Insurance Company now owns 355,656 shares of the medical device company’s stock worth $28,738,000 after buying an additional 8,068 shares during the last quarter. C WorldWide Group Holding A S boosted its stake in shares of DexCom by 14.2% in the 3rd quarter. C WorldWide Group Holding A S now owns 322,000 shares of the medical device company’s stock worth $25,934,000 after buying an additional 40,000 shares during the last quarter. Finally, SeaTown Holdings Pte. Ltd. purchased a new position in shares of DexCom in the 3rd quarter worth $3,584,000. 94.01% of the stock is currently owned by hedge funds and other institutional investors.

DexCom Trading Down 0.3 %

Shares of NASDAQ DXCM opened at $106.03 on Wednesday. The business’s 50 day moving average is $112.85 and its two-hundred day moving average is $99.36. The company has a debt-to-equity ratio of 1.08, a current ratio of 3.77 and a quick ratio of 3.43. DexCom, Inc. has a 1-year low of $66.89 and a 1-year high of $134.76. The stock has a market capitalization of $40.95 billion, a P/E ratio of 195.45, a PEG ratio of 2.95 and a beta of 1.14.

DexCom (NASDAQ:DXCMGet Rating) last announced its earnings results on Thursday, October 27th. The medical device company reported $0.28 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.24 by $0.04. The business had revenue of $769.60 million during the quarter, compared to analyst estimates of $752.67 million. DexCom had a return on equity of 13.27% and a net margin of 8.24%. As a group, research analysts expect that DexCom, Inc. will post 0.79 EPS for the current year.

Insider Buying and Selling

In related news, CEO Kevin R. Sayer sold 45,607 shares of the business’s stock in a transaction that occurred on Friday, January 20th. The shares were sold at an average price of $105.75, for a total value of $4,822,940.25. Following the completion of the transaction, the chief executive officer now owns 426,645 shares of the company’s stock, valued at $45,117,708.75. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. In other news, EVP Paul R. Flynn sold 8,988 shares of the company’s stock in a transaction on Thursday, December 8th. The stock was sold at an average price of $123.50, for a total transaction of $1,110,018.00. Following the transaction, the executive vice president now directly owns 55,744 shares of the company’s stock, valued at $6,884,384. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, CEO Kevin R. Sayer sold 45,607 shares of the company’s stock in a transaction on Friday, January 20th. The stock was sold at an average price of $105.75, for a total value of $4,822,940.25. Following the transaction, the chief executive officer now directly owns 426,645 shares in the company, valued at $45,117,708.75. The disclosure for this sale can be found here. Insiders sold 57,819 shares of company stock valued at $6,294,063 over the last 90 days. Corporate insiders own 0.41% of the company’s stock.

Wall Street Analysts Forecast Growth

DXCM has been the topic of several analyst reports. Wells Fargo & Company lifted their target price on DexCom from $102.00 to $128.00 and gave the company an “overweight” rating in a research report on Friday, October 28th. Citigroup lifted their target price on DexCom from $117.00 to $146.00 and gave the company a “buy” rating in a research report on Monday, December 12th. Cowen lifted their target price on DexCom from $85.00 to $114.00 in a research report on Friday, October 28th. Morgan Stanley lifted their target price on DexCom from $117.00 to $131.00 and gave the company an “equal weight” rating in a research report on Friday, January 6th. Finally, Jefferies Financial Group initiated coverage on DexCom in a research report on Wednesday, October 12th. They set a “buy” rating and a $125.00 target price on the stock. Three equities research analysts have rated the stock with a hold rating and ten have issued a buy rating to the company’s stock. According to data from MarketBeat.com, DexCom presently has a consensus rating of “Moderate Buy” and a consensus target price of $122.00.

DexCom Company Profile

(Get Rating)

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM system for diabetes management; Dexcom Real-Time API, which enables invited third-party developers to integrate real-time CGM data into their digital health applications and devices; Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions; and Dexcom Share, a remote monitoring system.

Featured Stories

Want to see what other hedge funds are holding DXCM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for DexCom, Inc. (NASDAQ:DXCMGet Rating).

Institutional Ownership by Quarter for DexCom (NASDAQ:DXCM)

Receive News & Ratings for DexCom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom and related companies with MarketBeat.com's FREE daily email newsletter.